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Over the past 5 years, the Asklepios Study Group haspublished >50 articles describing the results of their
epidemiological studies of preclinical heart disease.
Supported throughout by Thierry Gillebert, MD, PhD,
FESC, professor of medicine and cardiology at Ghent
University, Ghent, Belgium, the principal investigator of
the Asklepios Project, is Ernst Rietzschel, MD, PhD (see
http://circ.ahajournals.org/cgi/reprint/ 117/8/f43), who set
up the Asklepios Study Group for his PhD in 2002.
The Asklepios Study Group comprises the Asklepios
association of primary care physicians in Erpe-Mere
(between Brussels, Belgium, and Ghent) and 4 departments
at Ghent University: the Department of Cardiology (Ernst
Rietzschel and Marc De Buyzere); the Department of
Public Health (Professor Guy de Backer and Professor
Dirk De Bacquer); the Department of Biomedical
Technology (Patrick Segers and Pascal Verdonck); and the
Department of Molecular Biotechnology (Sofie Bekaert, a
specialist in telomere biology).
The Asklepios Project has become one of the main epi-
demiological projects worldwide, and will lead to more
major articles over the next 20 years.
“In a Way It Is an Approach to Vascular Ageing”
In the first phase of the project, from 2002 to 2004, >2500
healthy subjects between the ages of 35 and 55 were exam-
ined.1 The 2500 datasets, comprising mainly tonometry of
the arteries and distensibility of carotid arteries and femoral
arteries, were then analysed by the engineers.2 “We show
what happens with age in men and women with all these
different parameters,” says Professor Gillebert. “In a way,
it is an approach to define successful vascular ageing.”
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Thierry Gillebert, professor of medicine and cardiology, Ghent University, Ghent, Belgium, talks to
Jennifer Taylor, BSc, MSc, MPhil about the Asklepios Project.
Spotlight: The Asklepios Project
One of the Main Epidemiological Projects of Preclinical Heart Disease Worldwide
Team 2011: The Asklepios Investigators from the University of Ghent, Ghent, Belgium, in front of a research building at the Faculty of
Medicine and Health Sciences on March 9, 2011. From left to right: epidemiologist Dirk De Bacquer; clinical chemist Marc De Buyzere;
principal investigator and cardiologist Ernst Rietzschel; hypertensive expert Luc Van Bortel; professor of medicine and cardiology
Thierry Gillebert; expert in telomere biology Sofie Bekaert; cardiovascular mechanics engineers Sebastian Vermeersch and Patrick
Segers. Photograph courtesy of Dries Gaerdelen from the Department of Cardiology.
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“The First Step Is How Does This Afterload of the
Heart Relate to Vascular Morphology and Vascular
Function? The ext Step Is How Does This Load on
the Heart Impact on Systolic and Diastolic Function?”
The next stage of the project was to apply previous physi-
ological work on load (wall stress) to the epidemiological
dataset. Professor Gillebert explains, “We look at the load
in these patients, we reconstruct the afterload of the heart,
and we look very carefully at all different aspects of these
afterloads.” This is the focus of the PhD thesis of Julio
Chirinos, MD, from the University of Pennsylvania,
Philadelphia, PA, who works in a department headed by
Professor Martin St. John Sutton, MBBS.
Dr Chirinos, whose PhD will be completed later this
year, has computed the load on the heart for all Asklepios
participants with a wide array of noninvasive tools and
looked at the effects of load patterns on diastole and mal-
adaptive remodelling. This is important for understanding
the complex interactions between the ageing vascular tree
and the heart, for instance, to explain how increased arterial
stiffness, pulse wave velocity, and reflected waves impact
on cardiac structure and function.
In a Circulation article in 2009, Dr Chirinos showed the
feasibility of doing a wall stress time curve, which reveals
how much load the cardiac muscle faces throughout systole
at each moment of systole.3 “After this proof of concept, he
showed that he could do that in >2000 subjects,” says
Professor Gillebert. “This is wonderful, and we are using
these data to go further. The first step is, how does this
afterload of the heart relate to vascular morphology and
vascular function? The next step is, how does this load on
the heart impact on systolic and diastolic function? And
then the circle is closed.”
Dr Chirinos has used the data to construct equations
that account for body size and body weight when evaluat-
ing the mass of the left ventricle.4 Left ventricular mass is
primarily determined by body size and blood pressure, so
to calculate the effect of blood pressure it is necessary to
eliminate the effect of body size.
The Main Goals of the Second Round of
the Asklepios Project Are to Look at
Successful Vascular and Cardiac Ageing
The second round of the Asklepios Project beginning on
April 1, 2011, will run until 2014.
New ancillary research foci in the second round include
pulmonary diseases, sleep apnoea, hormonal influences,
early-stage kidney disease, sound and small particle pollu-
tion, besides the ongoing interest in epigenetics. The initial
2500 participants will be followed up, after 8 years, and a
cohort of 800 new subjects has been added to look for sec-
ular trends in parameters.
In the spirit of continuing to combine physiology with
epidemiological data, a stress test will be conducted on all
subjects. Data on major adverse cardiac events will also be
collected. The main goal is to look at successful vascular
and cardiac ageing.
Professor Gillebert is currently pursuing European
funding for this next phase. He says, “What we showed in
the physiological articles is that, with just baseline data, you
see just the tip of the iceberg, but if you look at an evolu-
tion or an intervention, then you can look at changes, and
this is far more powerful from the methodological point of
view.” He adds, “You need 10 times more funding for an
epidemiological project than you need for a basic science
project, and one of the problems we have, at both the
university and scientific foundation levels, is that, in the
decision-making jury, you always have basic scientists, and
basic scientists sometimes do not understand the impor-
tance and relevance of epidemiological research. They do
not always see that you start similarly with an experimen-
tal hypothesis, you try to get the answer in the data, and this
is as rigorous as physiological research.”
As epidemiological studies go, the Asklepios Project is
not as big or old as the Framingham Heart Study, but it is
complementary, and joint work on genetics has been con-
ducted with several other leading international cohorts.
Professor Gillebert is proud of the achievements of the
Asklepios Study Group, which have come to fruition
through the efforts of people he has coached and collabo-
rated with. He says, “We had to fight for this study, and we
had to fight for our careers because when you do something
like that, not everyone will go with you. However, on the
other hand, it was a very good investment, and everyone
presently agrees with that.”
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